. 2014 Oct;8().
doi: 10.4137/BCBCR.S9454.

Update on adjuvant chemotherapy for early breast cancer

Murtuza M Rampurwala 1 Gabrielle B Rocque 2 Mark E Burkard 1 
  • PMID: 25336961
  •     85 References
  •     18 citations


Breast cancer is the second most common cancer in women worldwide. Although most women are diagnosed with early breast cancer, a substantial number recur due to persistent micro-metastatic disease. Systemic adjuvant chemotherapy improves outcomes and has advanced from first-generation regimens to modern dose-dense combinations. Although chemotherapy is the cornerstone of adjuvant therapy, new biomarkers are identifying patients who can forego such treatment. Neo-adjuvant therapy is a promising platform for drug development, but investigators should recognize the limitations of surrogate endpoints and clinical trials. Previous decades have focused on discovering, developing, and intensifying adjuvant chemotherapy. Future efforts should focus on customizing therapy and reducing chemotherapy for patients unlikely to benefit. In some cases, it may be possible to replace chemotherapy with treatments directed at specific genetic or molecular breast cancer subtypes. Yet, we anticipate that chemotherapy will remain a critical component of adjuvant therapy for years to come.

Keywords: metastases; neoadjuvant; pathologic response; toxicity.

Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes.
Edith A Perez.
Clin Breast Cancer, 2004 Feb 03; 4 Suppl 3. PMID: 14754468
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
José Baselga, Mario Campone, +18 authors, Gabriel N Hortobagyi.
N Engl J Med, 2011 Dec 14; 366(6). PMID: 22149876    Free PMC article.
Highly Cited.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, +12 authors, EMILIA Study Group.
N Engl J Med, 2012 Oct 02; 367(19). PMID: 23020162    Free PMC article.
Highly Cited.
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
Sandra M Swain, Fredrick S Whaley, Michael S Ewer.
Cancer, 2003 May 27; 97(11). PMID: 12767102
Highly Cited.
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
Ines Vaz-Luis, Rebecca A Ottesen, +10 authors, Nancy U Lin.
J Clin Oncol, 2014 Jun 04; 32(20). PMID: 24888816    Free PMC article.
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Thomas J Smith, James Khatcheressian, +19 authors, Antonio C Wolff.
J Clin Oncol, 2006 May 10; 24(19). PMID: 16682719
Highly Cited.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737
Highly Cited.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, +23 authors, Michael Untch.
Lancet Oncol, 2014 May 06; 15(7). PMID: 24794243
Highly Cited.
Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
Roy E Smith, John Bryant, +2 authors, National Surgical Adjuvant Breast and Bowel Project Experience.
J Clin Oncol, 2003 Mar 29; 21(7). PMID: 12663705
Histological grading of breast carcinomas: a study of interobserver agreement.
P Robbins, S Pinder, +5 authors, C Elston.
Hum Pathol, 1995 Aug 01; 26(8). PMID: 7635449
Highly Cited.
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.
K Gudmundsdottir, A Ashworth.
Oncogene, 2006 Sep 26; 25(43). PMID: 16998501
Highly Cited. Review.
1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.
B Fisher, P Carbone, +9 authors, E R Fisher.
N Engl J Med, 1975 Jan 16; 292(3). PMID: 1105174
Highly Cited.
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, +21 authors, Breast Cancer International Research Group.
N Engl J Med, 2011 Oct 14; 365(14). PMID: 21991949    Free PMC article.
Highly Cited.
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Carboplatin in combination therapy for metastatic breast cancer.
Edith A Perez.
Oncologist, 2004 Oct 13; 9(5). PMID: 15477636
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 Apr 12; 24(13). PMID: 16606972
Highly Cited.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, +17 authors, Pinuccia Valagussa.
Lancet Oncol, 2011 Dec 14; 13(1). PMID: 22153890
Highly Cited.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Louis Fehrenbacher, Angela M Capra, +3 authors, Laurel A Habel.
J Clin Oncol, 2014 Jun 04; 32(20). PMID: 24888815
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.
G C Wishart, C D Bajdik, +34 authors, P D P Pharoah.
Br J Cancer, 2012 Aug 02; 107(5). PMID: 22850554    Free PMC article.
Side effects of adjuvant treatment of breast cancer.
C L Shapiro, A Recht.
N Engl J Med, 2001 Jun 30; 344(26). PMID: 11430330
Highly Cited. Review.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
Miguel Martín, Miguel A Seguí, +29 authors, GEICAM 9805 Investigators.
N Engl J Med, 2010 Dec 03; 363(23). PMID: 21121833
Ten-year results of FAC adjuvant chemotherapy trial in breast cancer.
A U Buzdar, S W Kau, T L Smith, G N Hortobagyi.
Am J Clin Oncol, 1989 Apr 01; 12(2). PMID: 2705401
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Rebecca A Dent, Geoffrey J Lindeman, +7 authors, James Carmichael.
Breast Cancer Res, 2013 Sep 26; 15(5). PMID: 24063698    Free PMC article.
Highly Cited.
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
José Baselga, Vladimir Semiglazov, +17 authors, Hope S Rugo.
J Clin Oncol, 2009 Apr 22; 27(16). PMID: 19380449
Highly Cited.
Sequential combination chemotherapy in advanced breast cancer.
C Brambilla, P Valagussa, G Bonadonna.
Cancer Chemother Pharmacol, 1978 Jan 01; 1(1). PMID: 373906
Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
B Fisher, A M Brown, +7 authors, C G Kardinal.
J Clin Oncol, 1990 Sep 01; 8(9). PMID: 2202791
Highly Cited.
Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles.
Lauren M Zasadil, Kristen A Andersen, +6 authors, Beth A Weaver.
Sci Transl Med, 2014 Mar 29; 6(229). PMID: 24670687    Free PMC article.
Highly Cited.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.
N Wolmark, J Wang, +2 authors, B Fisher.
J Natl Cancer Inst Monogr, 2002 Jan 05; (30). PMID: 11773300
Highly Cited.
Deconstructing the molecular portraits of breast cancer.
Aleix Prat, Charles M Perou.
Mol Oncol, 2010 Dec 15; 5(1). PMID: 21147047    Free PMC article.
Highly Cited. Review.
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
J M Nabholtz, K Gelmon, +8 authors, B Winograd.
J Clin Oncol, 1996 Jun 01; 14(6). PMID: 8656254
Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.
Jo Anne Zujewski, Leah Kamin.
Future Oncol, 2008 Oct 17; 4(5). PMID: 18922117
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Edith A Perez, Edward H Romond, +7 authors, Norman Wolmark.
J Clin Oncol, 2011 Jul 20; 29(25). PMID: 21768458    Free PMC article.
Highly Cited.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, +34 authors, Gunter von Minckwitz.
Lancet, 2014 Feb 18; 384(9938). PMID: 24529560
Highly Cited. Review.
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.
B Fisher, S Anderson, +18 authors, N Wolmark.
J Clin Oncol, 1999 Nov 05; 17(11). PMID: 10550131
Evolving concepts in the systemic adjuvant treatment of breast cancer.
G Bonadonna.
Cancer Res, 1992 Apr 15; 52(8). PMID: 1559216
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
A Schneeweiss, S Chia, +10 authors, J Cortés.
Ann Oncol, 2013 May 25; 24(9). PMID: 23704196
Highly Cited.
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.
Mark E Burkard, Kari B Wisinski, +11 authors, Amye J Tevaarwerk.
Clin Breast Cancer, 2013 Dec 18; 14(3). PMID: 24342730    Free PMC article.
The importance of dose intensity in the outcome of chemotherapy.
W M Hryniuk.
Important Adv Oncol, 1988 Jan 01;. PMID: 3042601
Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.
R Maisano, M Zavettieri, +4 authors, M Nardi.
J Chemother, 2011 Apr 13; 23(1). PMID: 21482494
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
José Baselga, Javier Cortés, +12 authors, CLEOPATRA Study Group.
N Engl J Med, 2011 Dec 14; 366(2). PMID: 22149875    Free PMC article.
Highly Cited.
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Eleftherios P Mamounas, John Bryant, +7 authors, Norman Wolmark.
J Clin Oncol, 2005 May 18; 23(16). PMID: 15897552
Highly Cited.
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Lawrence N Shulman, Constance T Cirrincione, +12 authors, Clifford Hudis.
J Clin Oncol, 2012 Jul 25; 30(33). PMID: 22826271    Free PMC article.
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
Stephen Jones, Frankie Ann Holmes, +17 authors, Michael A Savin.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204201
Highly Cited.
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.
Ingrid E Wertz, Saritha Kusam, +24 authors, Vishva M Dixit.
Nature, 2011 Mar 04; 471(7336). PMID: 21368834
Highly Cited.
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
M Martin, A Villar, +13 authors, GEICAM Group (Spanish Breast Cancer Research Group), Spain.
Ann Oncol, 2003 Jun 11; 14(6). PMID: 12796019
Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.
G Bonadonna, P Valagussa, +4 authors, U Veronesi.
Breast Cancer Res Treat, 1985 Jan 01; 5(2). PMID: 3839424
Expression and amplification of cyclin genes in human breast cancer.
M F Buckley, K J Sweeney, +7 authors, R L Sutherland.
Oncogene, 1993 Aug 01; 8(8). PMID: 8336939
Highly Cited.
Clinical evaluation of adriamycin, a new antitumour antibiotic.
G Bonadonna, S Monfardini, M De Lena, F Fossati-Bellani.
Br Med J, 1969 Aug 30; 3(5669). PMID: 5257148    Free PMC article.
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
Andrea Rocca, Alberto Farolfi, +2 authors, Dino Amadori.
Expert Opin Pharmacother, 2013 Dec 27; 15(3). PMID: 24369047
Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.
A Paradiso, F Schittulli, +4 authors, M De Lena.
J Clin Oncol, 2001 Oct 02; 19(19). PMID: 11579113
Phase II evaluation of adriamycin in human neoplasia.
R M O'Bryan, J K Luce, +3 authors, G Bonadonna.
Cancer, 1973 Jul 01; 32(1). PMID: 4716773
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Cancer stem cells: an old idea--a paradigm shift.
Max S Wicha, Suling Liu, Gabriela Dontu.
Cancer Res, 2006 Feb 21; 66(4). PMID: 16488983
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Miguel Martín, Alvaro Rodríguez-Lescure, +33 authors, GEICAM 9906 Study Investigators.
J Natl Cancer Inst, 2008 May 29; 100(11). PMID: 18505968
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Hyman B Muss, Donald A Berry, +7 authors, Cancer and Leukemia Group B Experience.
J Clin Oncol, 2007 Aug 21; 25(24). PMID: 17704418
Acute myeloid leukemia.
B Löwenberg, J R Downing, A Burnett.
N Engl J Med, 1999 Sep 30; 341(14). PMID: 10502596
Highly Cited. Review.
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs.
Karen E Gascoigne, Stephen S Taylor.
Cancer Cell, 2008 Jul 29; 14(2). PMID: 18656424
Highly Cited.
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Joseph A Sparano, Molin Wang, +7 authors, Nancy E Davidson.
N Engl J Med, 2008 Apr 19; 358(16). PMID: 18420499    Free PMC article.
Highly Cited.
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
Sandra M Swain, Jong-Hyeon Jeong, +14 authors, Norman Wolmark.
N Engl J Med, 2010 Jun 04; 362(22). PMID: 20519679    Free PMC article.
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.
C A Drukker, J M Bueno-de-Mesquita, +10 authors, S C Linn.
Int J Cancer, 2013 Feb 02; 133(4). PMID: 23371464    Free PMC article.
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
Carlos H Barcenas, Jiangong Niu, +6 authors, Sharon H Giordano.
J Clin Oncol, 2014 May 29; 32(19). PMID: 24868022    Free PMC article.
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.
D R Budman, D A Berry, +8 authors, E Frei.
J Natl Cancer Inst, 1998 Aug 27; 90(16). PMID: 9719081
Highly Cited.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
M De Lena, C Brambilla, A Morabito, G Bonadonna.
Cancer, 1975 Apr 01; 35(4). PMID: 1116104
Long-term followup of breast cancer patients: the 30-year report.
F Adair, J Berg, L Joubert, G F Robbins.
Cancer, 1974 Apr 01; 33(4). PMID: 4819216
Highly Cited.
Cancer statistics, 2014.
Rebecca Siegel, Jiemin Ma, Zhaohui Zou, Ahmedin Jemal.
CA Cancer J Clin, 2014 Jan 09; 64(1). PMID: 24399786
Highly Cited.
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
Christos Sotiriou, Pratyaksha Wirapati, +17 authors, Mauro Delorenzi.
J Natl Cancer Inst, 2006 Feb 16; 98(4). PMID: 16478745
Highly Cited.
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, +15 authors, Norman Wolmark.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258986
Highly Cited.
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
John R Mackey, Miguel Martin, +28 authors, TRIO/BCIRG 001 investigators.
Lancet Oncol, 2012 Dec 19; 14(1). PMID: 23246022
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, +11 authors, Alan Ashworth.
Nature, 2005 Apr 15; 434(7035). PMID: 15829967
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Wolfgang Eiermann, Tadeusz Pienkowski, +15 authors, John R Mackey.
J Clin Oncol, 2011 Sep 14; 29(29). PMID: 21911726
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer.
C Dickson, V Fantl, +6 authors, G Peters.
Cancer Lett, 1995 Mar 23; 90(1). PMID: 7720042
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Ivana Sestak, Mitch Dowsett, +4 authors, Jack Cuzick.
J Natl Cancer Inst, 2013 Sep 14; 105(19). PMID: 24029245    Free PMC article.
Highly Cited.
Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.
Gabrielle Rocque, Adedayo Onitilo, +8 authors, Mark E Burkard.
Breast Cancer Res Treat, 2011 Nov 09; 131(2). PMID: 22065290    Free PMC article.
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Miguel Martín, Amparo Ruiz, +27 authors, Ana Lluch.
J Clin Oncol, 2013 Jun 05; 31(20). PMID: 23733779
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, +14 authors, Eric P Winer.
J Clin Oncol, 2014 Aug 06; 33(1). PMID: 25092775    Free PMC article.
Highly Cited.
Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.
B Fisher, R G Ravdin, +3 authors, R J Noer.
Ann Surg, 1968 Sep 01; 168(3). PMID: 4970947    Free PMC article.
Highly Cited.
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, +22 authors, FinHer Study Investigators.
N Engl J Med, 2006 Feb 24; 354(8). PMID: 16495393
Highly Cited.
Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy.
Natalia V Danilova, Zhomart R Kalzhanov, +4 authors, Ospan A Mynbaev.
Int J Nanomedicine, 2015 Apr 08; 10. PMID: 25848260    Free PMC article.
The double face of Morgana in tumorigenesis.
Mara Brancaccio, Stefania Rocca, +2 authors, Federica Fusella.
Oncotarget, 2015 Oct 16; 6(40). PMID: 26460959    Free PMC article.
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Tieying Dong, Xinmei Kang, +6 authors, Qingyuan Zhang.
Tumour Biol, 2015 Dec 31; 37(6). PMID: 26715276
Mathematical models of breast and ovarian cancers.
Dana-Adriana Botesteanu, Stanley Lipkowitz, Jung-Min Lee, Doron Levy.
Wiley Interdiscip Rev Syst Biol Med, 2016 Jun 04; 8(4). PMID: 27259061    Free PMC article.
Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know.
Chad M Teven, Daniel B Schmid, +2 authors, Michael A Howard.
Eplasty, 2017 Mar 16; 17. PMID: 28293332    Free PMC article.
CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer.
Xinyu Deng, Sophia Apple, +7 authors, Helena R Chang.
Oncotarget, 2017 Apr 19; 8(24). PMID: 28418843    Free PMC article.
Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial.
Safa Najafi, Mehrdad Payandeh, +3 authors, Fereshte Abbasvandi.
Contemp Oncol (Pozn), 2017 Apr 25; 21(1). PMID: 28435404    Free PMC article.
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.
Shenghui He, Patrick J Roberts, +10 authors, Norman E Sharpless.
Sci Transl Med, 2017 Apr 28; 9(387). PMID: 28446688    Free PMC article.
Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer.
Skye Hung-Chun Cheng, Tzu-Ting Huang, +6 authors, Ben-Long Yu.
PLoS One, 2017 Sep 09; 12(9). PMID: 28886126    Free PMC article.
Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death.
Naoshad Muhammad, Robert Steele, +2 authors, Ratna B Ray.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029506    Free PMC article.
Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs.
Jessica Gambardella, Bruno Trimarco, Guido Iaccarino, Daniela Sorriento.
Oxid Med Cell Longev, 2017 Dec 05; 2017. PMID: 29201269    Free PMC article.
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
Steffen Dörfel, Claus-Christoph Steffens, +6 authors, TMK-Group (Tumour Registry Breast Cancer).
Breast Cancer, 2017 Dec 06; 25(3). PMID: 29204847    Free PMC article.
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Karen A Cadoo, Peter A Kaufman, +3 authors, Tiffany A Traina.
Clin Breast Cancer, 2018 Jun 14; 18(6). PMID: 29895438    Free PMC article.
CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
Bray Denard, Sharon Jiang, Yan Peng, Jin Ye.
BMC Cancer, 2018 Aug 15; 18(1). PMID: 30103710    Free PMC article.
Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer.
Assunta Sellitto, Ylenia D'Agostino, +10 authors, Francesca Rizzo.
Cancers (Basel), 2020 Jun 11; 12(6). PMID: 32516978    Free PMC article.
CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis.
Dongwei Dou, Xiaoyang Ren, +5 authors, Song Zhao.
Cancer Cell Int, 2020 Sep 19; 20. PMID: 32944002    Free PMC article.
Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study.
Junjie Li, Zhimin Shao, +8 authors, Ziwei Ying.
Medicine (Baltimore), 2018 May 26; 97(21). PMID: 29794725    Free PMC article.
Drug combination and repurposing for cancer therapy: the example of breast cancer.
Ana Salomé Correia, Fátima Gärtner, Nuno Vale.
Heliyon, 2021 Jan 26; 7(1). PMID: 33490692    Free PMC article.